High quality Mifepristone CAS 84371-65-3 for early pregnant, push the stop pregnancy, fetal intrauterine death induced labor
Place of Origin:ShenZhen, China (Mainland)
Type:Endocrine System Agents
Grade Standard:Medicine Grade
Usage: for early pregnant, push the stop pregnancy, fetal intrauterine death induced labor
Mifepristone is the active ingredient in the so-called abortion pill RU-486 (trade name: Mifegyne). Mifepristone is a progesterone receptor antagonist. It inhibits the action of the progestin progestin by having a five-fold higher affinity for the receptors of this hormone. Furthermore, it blocks the receptors for glucocorticoids by a threefold higher affinity for dexamethasone. Mifepristone is also being developed for the treatment of rarely occurring hypercortisolism (Cushing's syndrome).
Taking mifepristone in pregnancy leads to opening of the cervix and detachment of the uterine lining within 48 hours. After 36 to 48 hours, the pregnant woman applies a prostaglandin, for example, gemeprost or misoprostol. The prostaglandin tablets are either ingested or inserted into the vagina. This causes the uterus to contract, trigger an artificial abortion, and expel the fruit. Mifepristone is effective throughout the pregnancy but, according to studies, has the highest success rate before the 49th day. The effect on the cervix is also given to non-pregnant women and is used before certain gynecological procedures.
In the treatment of Cushing's disease, mifepristone is believed to act as a glucocorticoid receptor antagonist. The blockade of the receptor suppresses the binding of the natural ligand cortisol and consequently its action.
Development and approval
Mifepriston was developed by Hoechst subsidiary Roussel-Uclaf in the 1980s. Even before the approval, it caused a stir - parts of the women's movement welcomed the development of the drug, abortion opponents ran against it. First, it was approved under the trade name Mifegyne 1988 in France. Just one month after the market launch, it had to be withdrawn for political reasons. It was only released on the express request of the Minister of Health. In 1991 it was approved in the UK, in 1992 in Sweden. The approval in Germany should be applied for only if a social consensus was found.
In 1997, Hoechst transferred the rights to the active substance free of charge to the inventor Edouard Sakiz. Soon followed by approval in other countries; Mifepristone has been approved in Germany and most other European countries since 1999.
Breast-taking was originally allowed until the 7th week of gestation (49th day) after the last menstruation, in the UK and Sweden until the 63rd day. In 2007, the EU Commission ordered a change of registration to the member states, which standardized the scope of the treatment on abortion by the 9th week (63rd day) - with subsequent use of a prostaglandin analogue - across the EU.  In Switzerland, admission is still valid until the 49th day. For medically necessary abortions, mifepristone is also approved later in pregnancy and is currently (in combination with misoprostol) the most efficient method. However, there are many so-called off-label applications: Up to the 12th week, other dosage, other indications such as endometriosis (proliferation of the uterine lining) or as a pill afterwards.
According to § 47a of the German Medicines Act, this medicinal product may only be given directly to certain institutions in which abortions are performed and only on prescription of a doctor treating there. It must not be placed on the pharmacy in the market.
Most side effects are not attributable to Mifegyne but to prostaglandin: mild side effects may include nausea, vomiting, diarrhea, headache, hot flashes. Often the uterine / (uterine) contractions cause more or less severe pain. Severe bleeding occurs in about 5% of cases and may require curettage in up to 1.4% of cases. Infections have been reported in less than 5% of women. Rupture of uterus after prostaglandin uptake has been reported in rare cases during initiation of termination of pregnancy in the second trimester or induction of labor due to fetal death in utero during the third trimester. This particularly affected multiple pregnancies or patients with caesarean scar. Failure rate: 1.3% to 7.5%. A teratogenic effect of Mifegyne (damage to the embryo) can not be completely ruled out. For misoprostol (Cytotec) it is accepted. Therefore, in approximately 1% of cases in which the pregnancy continues to develop, women are urgently advised to stop the surgery.